Jazz PharmaceuticalsJAZZ
JAZZ
About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Employees: 2,800
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
82% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $15.9M
52% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 50
50% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 9 (+3) [Q3]
4% more funds holding
Funds holding: 448 [Q2] → 468 (+20) [Q3]
1.14% more ownership
Funds ownership: 94.71% [Q2] → 95.85% (+1.14%) [Q3]
3% more capital invested
Capital invested by funds: $6.38B [Q2] → $6.59B (+$211M) [Q3]
3% more repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 156
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$162
21%
upside
Avg. target
$182
36%
upside
High target
$207
55%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler David Amsellem 50% 1-year accuracy 20 / 40 met price target | 22%upside $163 | Overweight Reiterated | 12 Dec 2024 |
RBC Capital Gregory Renza 30% 1-year accuracy 26 / 86 met price target | 34%upside $179 | Outperform Reiterated | 12 Dec 2024 |
Needham Ami Fadia 47% 1-year accuracy 78 / 167 met price target | 55%upside $207 | Buy Reiterated | 12 Dec 2024 |
HC Wainwright & Co. Oren Livnat 54% 1-year accuracy 25 / 46 met price target | 49%upside $200 | Buy Reiterated | 22 Nov 2024 |
Baird Joel Beatty 60% 1-year accuracy 24 / 40 met price target | 21%upside $162 | Outperform Maintained | 18 Nov 2024 |
Financial journalist opinion
Based on 4 articles about JAZZ published over the past 30 days
Neutral
PRNewsWire
19 hours ago
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
DUBLIN , Feb. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.
Positive
Zacks Investment Research
6 days ago
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Positive
Seeking Alpha
2 weeks ago
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Positive
Seeking Alpha
4 weeks ago
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels.
Positive
Seeking Alpha
1 month ago
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven by zanidatamab's approval and other key drugs like Rylaze and Zepzelca, crucial for achieving Vision 2025 sales goals.
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference.
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals Announces CEO Succession Plan
Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN , Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025.
Neutral
Zacks Investment Research
2 months ago
5 High ROE Stocks to Buy as Volatility Weighs on Markets
DIS, LDOS, RF, FTNT and JAZZ are some of the stocks with high ROE to profit from as intense volatility spooks markets.
Neutral
PRNewsWire
2 months ago
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improvements in severity of behavioral symptoms Real-world data from the BECOME (BEhavior, COgnition and More with Epidiolex®) surveys, which show outcomes reported by long-term care facility nurses and tuberous sclerosis complex caregivers For U.S. media and investors only DUBLIN , Dec. 6, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced nine company-sponsored Epidiolex ® (cannabidiol) posters are being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California. Data presented at the meeting includes updated analyses of real-world data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, which characterizes and quantifies seizure and non-seizure outcomes in patients with epilepsy and tuberous sclerosis complex (TSC) treated with Epidiolex.
Neutral
PRNewsWire
2 months ago
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United States For U.S. media and investors only DUBLIN , Dec. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for injection for intravenous use is recommended by the National Comprehensive Cancer Network® (NCCN ® ) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A treatment option for Biliary Tract Cancers (BTC). Ziihera was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 20, 2024, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC, as detected by an FDA-approved test.
Charts implemented using Lightweight Charts™